Please provide your email address to receive an email when new articles are posted on . The FDA granted a new indication to a cryoballoon ablation catheter that allows it to be used as a first-line ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and ...

Use of catheter ablation is not only beneficial for treating atrial flutter but also can significantly reduce hospital visits – both inpatient and emergency – and lower the risk for atrial ...

Please provide your email address to receive an email when new articles are posted on . A new cost-utility analysis has shown that catheter ablation as a second-line intervention is likely ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful ...

First-line treatment with catheter ablation is superior to drug therapy for reducing atrial fibrillation, according to five year results from the MANTRA-PAF trial presented for the first time at ESC ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Atrial fibrillation is the most common arrhythmia worldwide, affecting millions of the general population.

Among patients with atrial fibrillation, those with a recent stroke are at significantly higher risk of recurrence than those without. Catheter ablation is expected to reduce the risk of ...

Only a few months after Medtronic completed its acquisition of cardiac device maker Affera, the nearly billion-dollar buyout is already paying off. A dual-use catheter originally developed by Affera ...

The FDA approved the first pulsed field ablation (PFA) catheter, the PulseSelect PFA system, for the treatment of paroxysmal and persistent atrial fibrillation (Afib), Medtronic announced on Wednesday ...